Renee N. Donahue

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Julius Strauss, Christopher R. Heery, Jeffrey Schlom et al. · Clinical Cancer Research · 2018 · 415 citations · Full text

Medicine, Oncology, Pharmacology +17

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Fatima Karzai, David James VanderWeele, Ravi A. Madan et al. · Journal for ImmunoTherapy of Cancer · 2018 · 312 citations · Full text

Medicine, Oncology, Pharmacology +17

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

Christopher R. Heery, Geraldine O’Sullivan Coyne, Ravi A. Madan et al. · The Lancet Oncology · 2017 · 295 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

Marijo Bilušić, Christopher R. Heery, Julie Collins et al. · Journal for ImmunoTherapy of Cancer · 2019 · 273 citations · Full text

Medicine, Oncology, Pharmacology +17

Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine

Anna Kwilas, Andressa Ardiani, Renee N. Donahue et al. · Journal of Translational Medicine · 2014 · 190 citations · Full text

Medicine, Immunology, Oncology +17